Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

GlaxoSmithKline Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (226)
ARTG (117)
Australian Public Assessment Report (AusPAR) (40)
Prescription medicine registration (17)
Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)
Face mask cancellation (1)

Date

2024 (10)
2023 (18)
2022 (62)
2021 (12)
2020 (60)
2019 (31)
2018 (27)
2017 (24)
2016 (11)
2015 (51)
2014 (24)
2013 (9)
2012 (6)
2011 (4)
2010 (7)
2009 (3)
2008 (6)
2007 (6)
2006 (3)
2005 (4)
2004 (1)
2003 (3)
2002 (3)
2001 (1)
2000 (3)
1999 (4)
1998 (5)
1997 (4)
1995 (1)
1992 (2)
1991 (6)

Results for "[search-keyword]"

Search

Sponsor content

412 result(s) found, displaying 161 to 170

Lamictal Dispersible Tablets 100mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Lamictal Dispersible Tablets 25mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Lamictal Dispersible Tablets 5mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Lamictal Dispersible Tablets 50mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Lamictal Dispersible Tablets 200mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Valtrex Tablets Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Zeffix 100mg Tablets Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Naramig Tablets 2.5mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
TYKERB Lapatinib 250mg (as ditosylate monohydrate) tablets bottle pack (EXPORT ONLY) Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection (289257)

2 July 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection.

Pages

First page
Previous page
…
Page 13
Page 14
Page 15
Page 16
Current page 17
Page 18
Page 19
Page 20
Page 21
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.